• Vaccine Name: Brucella abortus L7/L12 Omp16 recombinant vector vaccine with Montanide Gel01 adjuvant
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009308
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Antigen: L7/L12; Omp16
• Adjuvant: Montanide Gel01
• Preparation: Influenza A viral vector expressing Brucella L7/L12 or Omp16 proteins formulated with Montanide Gel01 adjuvant. (Tabynov et al, 2014b)
• Description: The study introduces a novel influenza viral vector vaccine expressing Brucella ribosomal L7/L12 or Omp16 proteins combined with the adjuvant Montanide Gel01, designed for immunization of pregnant heifers. Efficacy: The vector vaccine provided good protection against Brucella abortus 544 infection, preventing abortion and reducing infection indices in heifers and their fetuses or calves; protection was comparable to commercial vaccines Brucella abortus strain 19 and strain RB51. (Tabynov et al, 2014b)

Cattle Response

• Vaccination Protocol: Pregnant heifers received influenza-vectored Brucella antigen prime-boost vaccination at 28-day intervals; administration routes varied by group (conjunctival or subcutaneous). (Tabynov et al, 2014b)
• Efficacy: The vector vaccine provided good protection against Brucella abortus 544 infection, preventing abortion and reducing infection indices in heifers and their fetuses or calves; protection was comparable to commercial vaccines Brucella abortus strain 19 and strain RB51. (Tabynov et al, 2014b)
• Description: Immunization of pregnant heifers via conjunctival or subcutaneous routes using a cross prime and booster vaccination schedule with a 28-day interval; comparison with positive controls vaccinated with Brucella abortus strain 19 or strain RB51 and a negative control group receiving PBS plus Montanide Gel01. (Tabynov et al, 2014b)